Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.
Estupiñán HY, Bouderlique T, He C, Berglöf A, Gupta D, Saher O, Daza Cruz MÁ, Peña-Perez L, Yu L, Zain R, Karlsson MCI, Månsson R, Smith CIE.
Estupiñán HY, et al. Among authors: berglof a.
Blood Adv. 2020 Jun 9;4(11):2439-2450. doi: 10.1182/bloodadvances.2019001319.
Blood Adv. 2020.
PMID: 32492159
Free PMC article.